PsyMed Ventures is an early-stage venture capital fund investing in frontier brain and mental health technologies, including neurotechnology, precision psychiatry, novel therapeutics, digital therapeutics, and AI-driven approaches. The firm typically invests $500K to $1.5M per portfolio company.
45% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Average disclosed round size is $20.2M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Remepy | Series A | $36M | Aug 2026 |
 Aerska | Seed | $21M | Oct 2025 |
 Ancilia | Unknown | $4.2M | Jul 2024 |
 Motif Neurotech | Series A | $18.8M | Jan 2024 |
 Jimini Health | Pre-Seed | $8M | Jan 2024 |
 Journey Clinical | Series A | — | Jan 2023 |
 Delix Therapeutics | Series A | $70M | Sep 2021 |
| Journey Clinical | Seed | $3M | Sep 2021 |
 Freedom Bioscience | Seed | $10.5M | — |
| NNEURODE | Pre-Seed | — | — |
| Remepy | Seed | $10M | — |
Top Co-Investors
Palo Santo3 shared
Gaingels3 shared
Fifty Years2 shared
Dolby Family Ventures2 shared
re.Mind Capital2 shared
97212 Ventures2 shared
NFX2 shared
Fresh.fund2 shared
GG12 shared
TechAviv2 shared
Solari Capital1 shared
Union Square Ventures1 shared
Coalition Operators1 shared
Mosaic Ventures1 shared
AlleyCorp1 shared
SV Angel1 shared
Able Partners1 shared
Norrsken VC1 shared
Speedinvest1 shared
Exor Ventures1 shared
Last updated: 20 October 2026